Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)

NCT06856577 is registered in ClinicalTrials.gov with Adverum Biotechnologies, Inc. as lead sponsor.

NCT NCT06856577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06856577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)
Lead sponsor
Adverum Biotechnologies, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 28, 2025
Completion date
November 23, 2030
Enrollment
311 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd), wet amd